

Original Research Article

Levels of Neutrophils, Interleukin-10 and Tumor Necrosis Factor-Alpha Amongst People Living with Coinfection of HIV and Malaria in Benin City, Edo state, Nigeria

ABSTRACT

Introduction: Malaria and HIV are prevalent in Sub-Saharan Africa, often leading to co-infection. In 2019, malaria affected nearly 229 million people worldwide, with the majority of cases in 29 African countries, particularly Nigeria and the Democratic Republic of the Congo. Despite progress in malaria control, the disease remains widespread, with millions of probable cases reported annually. HIV infection has been shown to limit the antibody response to malaria antigens. Tumor necrosis factor (TNF- α) is a key cytokine involved in immune modulation. Interleukin-10 (IL-10) is an important anti-inflammatory cytokine produced by various T cell subsets and is regulated by TGF- β . Neutrophils, the most abundant white blood cells, play a vital role in combating infections through phagocytosis and the release of antimicrobial substances. This study aims to evaluate the levels of neutrophils, IL-10, and TNF- α in individuals co-infected with HIV and malaria.

Aim: This study is aimed at investigating the levels of TNF- α , IL-10, and Neutrophils in study participants with coinfection of HIV and Malaria attending university of Benin teaching hospital.

Study Design: Cross-sectional study design was used

Methodology: The study was carried out at the University of Benin Teaching Hospital in Edo State, Nigeria. The study lasted for a period of six months (From January, 2024 to June, 2024). A total of 210 samples were collected and used in the study, which included adults with HIV infection, with Malaria Infection and with the co-infection of HIV and Malaria who met the inclusion criteria and were reconfirmed throughout the study period. All samples were analyzed for full blood counts using Mindray BC-5000. Subsequently, the samples were processed for ELISA to evaluate the levels of TNF-alpha, and IL-10.

Results: Individuals with HIV-Malaria coinfection exhibited significantly elevated levels of Tumor Necrosis Factor-Alpha (TNF- α) as compared to those with HIV or malaria, with $p < 0.001$ for both comparisons. Interleukin 10 (IL-10) levels were lower in co-infected individuals than in malaria only cases, $p < 0.001$, while neutrophil percentages were significantly reduced in coinfecting individuals compared to those with HIV, $p < 0.001$ and malaria, $p = 0.001$.

Conclusion: The study showed that individuals with HIV-Malaria coinfection had significantly higher TNF- α levels and lower neutrophil percentages compared to those with HIV alone. In

contrast, IL-10 levels were higher in those with malaria alone. Additionally, there were inverse correlations between TNF- α and neutrophils, and between IL-10 and TNF- α .

Keywords: HIV, Malaria, Co-infection, TNF-Alpha, IL-10, Neutrophils

UNDER PEER REVIEW

1.0 INTRODUCTION

Malaria alone affected almost 229 million people globally in 2019, with the majority (95%) of cases happening in 29 sub-Saharan African countries: Nigeria (27%), Democratic Republic of the Congo (12%), Uganda (5%), Mozambique (4%), and Niger (3%) [1]. Malaria and HIV, two of the world's deadliest diseases, share a large portion of territory in Sub-Saharan Africa. As a result, malaria and HIV co-infection are prevalent in the region [2].

An estimated 3.3–3.7 million probable cases of malaria occur in healthcare facilities annually, despite notable progress in recent years to reduce the burden of this infection due to the implementation of several strategic programs for malaria control [3][4]. Thus, the disease is still widely distributed. The breadth of the antibody response to merozoite surface protein (MSP) antigens is limited by HIV infection, as previous studies have shown [5].

Important roles in immune control are played by pro-inflammatory cytokines like tumor necrosis factor (TNF- α) and anti-inflammatory cytokines like interleukin 10 (IL-10). There are two types of TNF- α : transmembrane (mTNF- α) and soluble (sTNF- α), each having unique binding and functional characteristics [6]. Th1, Th2, Tr1, and regulatory T cells are among the T cell subsets that produce IL-10, which is essential for controlling immune responses and reducing inflammation [7]. The most common type of white blood cells, neutrophils, are critical for immune system modulation and pathogen removal [8].

The most common kind of white blood cells in the body are called neutrophils, also called polymorphonuclear cells [9]. Neutrophils have the ability to eliminate pathogens through phagocytosis, the production of reactive oxygen species (ROS) and other antimicrobial compounds, or the creation of Neutrophils extracellular traps (NETs) [8]. They can also help to activate and regulate the immune response by secreting cytokines and chemokines and possibly presenting antigens [10].

In this study, we evaluated the levels of Neutrophils, interleukin-10, and tumor necrosis factor alpha in individuals who co-infect with HIV and malaria.

2.0 MATERIALS AND METHOD

2.1 Study area

The research project was carried out at the University Of Benin Teaching Hospital (UBTH) in Benin City, Nigeria. UBTH, a premier tertiary healthcare institution in the country, provides an ideal setting for extensive research due to its state-of-the-art facilities and diverse patient population.

2.2 Study Design: Cross-sectional study design was used

2.3 Justification of the Study

The justification for the study on the levels of Tumor Necrosis Factor-Alpha, Interleukin 10, and Neutrophils in people living with coinfection of HIV and Malaria in Benin can be based on the following:

- **Synergistic Health Impact:** Research findings suggest that HIV and malaria parasites co-infection can act synergistically, resulting in worse health outcomes, including anemia, increased plasma viral load, decreased CD4 count, and more severe disease progression in affected individuals [11][12]. Understanding the specific immune responses triggered by this coinfection is crucial to mitigate the compounded health risks faced by individuals living with both diseases.
- **Public Health Implications:** The interaction between HIV and malaria poses significant public health implications, especially in regions like sub-Saharan Africa where both diseases are prevalent. The study of immune markers like TNF- α , IL-10, and Neutrophils in this context can provide insights into the mechanisms underlying the exacerbation of health conditions in co-infected individuals.

- **Clinical Management Strategies:** Identifying the alterations in immune markers in people with HIV-Malaria coinfection can inform the development of targeted therapeutic interventions and management strategies. For instance, preventing malaria in individuals living with HIV may lead to improved virologic response and prolonged period until HIV treatment is required, thereby alleviating the burden on antiretroviral programs in Africa [12].
- **Knowledge Gap:** Despite the known impact of HIV and malaria coinfection on health outcomes, there is still a lack of comprehensive understanding of the specific alterations in immune markers and their implications for clinical management [12]. Therefore, conducting a study on these immune responses is essential to bridge this knowledge gap and enhance the care of individuals with HIV-Malaria coinfection.

2.4 Objectives of the Study

- I. To determine the levels of Tumor Necrosis Factor-Alpha (TNF- α) in individuals with HIV-Malaria coinfection compared to those with HIV or Malaria infection alone.
- II. To assess the levels of Interleukin 10 (IL-10) in individuals with HIV-Malaria coinfection compared to those with HIV or Malaria infection alone.
- III. To investigate the levels of Neutrophils in individuals with HIV-Malaria coinfection compared to those with HIV or Malaria infection alone.
- IV. To explore the relationship between the levels of TNF- α , IL-10, and Neutrophils with clinical outcomes (e.g., disease severity, viral load, CD4 count) in individuals with HIV-Malaria coinfection.

2.5 Sample Size

Cochrane formula was used in calculating sample size.

Prevalence of malaria-HIV coinfection (p) = 0.229 (22.9% expressed as a proportion) [13].

Margin of error (EE) = 0.0569

Z-score for a 95% confidence level (Z) \approx 1.96

Using the formula:

$$n = \frac{Z^2 \times p \times (1-p)}{E^2}$$

Substituting the given values:

$$n = 1.96^2 \times 0.229 \times (1 - 0.229) / 0.0569^2$$

$$n = 3.8416 \times 0.176 / 0.00323$$

$$n = 0.6769 / 0.00323$$

$$n = 209.8$$

$$n \approx 210$$

Rounding up to the nearest whole number, a sample size of approximately 210 individuals was utilized.

2.6 Study Population

2.6.1 Inclusion criteria

Participants included in this research were 70 individuals diagnosed with both HIV and malaria, 70 individuals diagnosed with only malaria and 70 individuals diagnosed with only HIV confirmed through medical records or laboratory results at the University of Benin Teaching Hospital- were this information confirmed before study. To ensure consistency and reliability in

the study population, only patients who met the clinical criteria for both infections as per established diagnostic guidelines were considered eligible for inclusion.

2.6.2 Exclusion criteria

Individuals were excluded from the study if they met any of the following criteria:

1. Diagnosis of other types of infections or diseases that could interfere with immune responses or study outcomes.
2. Presence of severe co-morbidities or medical conditions that could significantly alter immune markers, such as cancer or autoimmune diseases.
3. Inability to provide informed consent or participate actively in the study due to cognitive impairment or other reasons.
4. Pregnancy, as hormonal changes during pregnancy can affect immune function and potentially confound study results.
5. Participation in any concurrent clinical trials or medical interventions that could influence the immune response or outcomes measured in this research.
6. HIV patients on ART

2.7 Equipments

Haematology Analyzer (Mindray BC-5000), Elisa Machine (BioTek Synergy HTX)

2.8 Data Collection Methods

2.8.1 Sample Collection

Venipuncture was used to obtain blood samples, which were then separated into two tubes using standard procedures. These tubes held 5 mL of blood for the neutrophil count and a plain tube for the measurement of TNF- α and IL-10.

2.8.2 Determination of Tumor Necrosis Factor α (TNF α)

Method:ELISA[14].

Principle:Tumor Necrosis Factor-Alpha (TNF- α) quantification assay uses sandwich ELISA technique: TNF- α from samples binds to microwells coated with a capture antibody specific to human TNF- α , which is followed by a biotin-conjugated detection antibody and streptavidin-HRP that binds to the detection antibody. Addition of a colorimetric substrate produces a color that is proportionate to TNF- α levels, measured at 450 nm.

Procedure:The process starts with prepping typical TNF- α dilutions and cleaning microwell strips. After washing, samples are added, and then the detecting antibody and streptavidin-HRP. An acid solution is used to monitor and halt the development of color. By comparing absorbance results against a standard curve made from known dilutions, TNF- α concentrations are obtained. This technique detects TNF- α in a variety of biological samples, such as serum and plasma, and is both sensitive and specific.

2.8.3 Determination of Interleukin-10 (IL-10).

Method:ELISA[15].

Principle:A microtiter plate coated with a monoclonal antibody specific to human IL-10 is used in the IL-10 test. Unbound components are removed by washing after the sample has been added. To identify bound IL-10, biotinylated antibody is added first, then streptavidin-HRP. Sulfuric acid stops the blue color that the TMB substrate produces in proportion to the levels of IL-10, turning the solution yellow. To calculate the amount of IL-10 present in the sample, the intensity of this yellow color is measured at 450 nm and compared to a standard curve.

Procedure:100 μ L of diluted standards and sample dilution buffer were added to designated wells for the IL-10 assay, and then 100 μ L of diluted samples were added. After two hours of

incubation at 37°C, the plate underwent three rounds of washing. After adding and incubating a working secondary antibody for an hour, another wash was performed. Subsequently, 100 µL of Streptavidin-HRP Conjugate was introduced and allowed to sit for half an hour. Following washing, blue-colored TMB Substrate was applied; this color changed to yellow when Stop Solution was introduced. At 450 nm, absorbance was measured.

2.8.4 Determination of Neutrophil count

Method: Haematology Analyzer (Mindray BC-5000) [16].

Principle: Both impedance-based and optical methods are used by the haematology analyzer to quantify neutrophils. Leukocytes are isolated from blood samples by diluting them with a lysing reagent. Impedance measurement measures changes in the cell as it passes through an electrical field, allowing for size and granularity differentiation. Simultaneously, optical analysis measures light scatter and fluorescence to obtain additional information on cell characteristics. This combined approach, processed through sophisticated algorithms, accurately determines the absolute neutrophil count (ANC) while correcting for potential interferences, ensuring precise neutrophil quantification in the sample.

Procedure: The sample was placed into the sample chamber of the haematology analyzer, and the researcher started the analysis. The analyzer then processed the data to determine the absolute neutrophil count, and the researcher checked the output on the analyzer's display and noted the results for additional analysis and reporting. The analyzer performed optical and impedance measurements to evaluate cell size and granularity during the analysis.

2.9 Statistical Analysis

Data from this study were analyzed using the Statistical Package for the Social Sciences (SPSS) version 29 for Windows 10. The numerical variables were assessed for normality using the Shapiro-Wilk test. Variables meeting the criteria for normal distribution were analyzed with parametric tests, while those deviating from normality were evaluated using non-parametric tests. Results were presented as means \pm standard deviation (SD). Comparisons of means between groups were conducted using the independent samples t-test and one-way analysis of variance (ANOVA). Statistical significance was set at $p < 0.05$, with $p > 0.05$ indicating non-significance.

3. RESULTS

Table 1 presents the levels of Tumor Necrosis Factor-Alpha (TNF- α) in individuals with HIV-Malaria coinfection compared to those with HIV or malaria infection alone. The table shows that the mean TNF- α level in individuals with HIV-Malaria coinfection was 27.67 ± 9.24 pg/ml. In contrast, individuals with HIV alone had a mean TNF- α level of 11.20 ± 2.17 pg/ml, and those with malaria infection alone had a mean TNF- α level of 13.23 ± 3.79 pg/ml. Statistical analysis revealed a significant difference in TNF- α levels between the HIV-Malaria coinfection group and the HIV-only group ($p < 0.001$), as well as between the HIV-Malaria coinfection group and the malaria-only group ($p < 0.001$).

| Parameter | HIV-Malaria coinfection n=70 | HIV n=70 | Malaria infection n=70 | p-value |
|---------------|---------------------------------|-----------------|---------------------------|---------|
| | Mean ±SD | | | |
| TNF-α (pg/ml) | 27.6667±9.23976 | 11.1994±2.17116 | - | <0.001* |
| | 27.6667± 9.23976 | - | 13.2317±3.78970 | <0.001* |

*p-value is significant at p<0.05

Table 2 displays the levels of Interleukin 10 (IL-10) in individuals with HIV-Malaria coinfection compared to those with HIV or malaria infection alone. The mean IL-10 level for individuals with HIV-Malaria coinfection was 18.74 ± 5.15 pg/ml. For those with HIV alone, the mean IL-10 level was slightly higher at 20.24 ± 8.89 pg/ml, but this difference was not statistically significant, as indicated by a p-value of 0.217. In contrast, individuals with malaria infection alone exhibited a significantly higher mean IL-10 level of 25.86 ± 7.05 pg/ml compared to those with HIV-Malaria coinfection ($p < 0.001$). The significant p-value highlights that the IL-10 levels in malaria-only cases are statistically different from those in HIV-Malaria coinfection cases, while no significant difference was observed between the HIV-only and HIV-Malaria coinfection groups.

| Parameter | HIV-Malaria coinfection n=70 | HIV n=70 | Malaria infection n=70 | p-value |
|---------------|---------------------------------|-----------------|---------------------------|---------|
| | Mean ± SD | | | |
| | 18.7350±5.15496 | 20.2414±8.89411 | - | 0.217 |
| IL-10 (pg/ml) | 18.7350±5.15496 | - | 25.8621±7.05089 | <0.001* |

*p-value is significant at p<0.05

Table 3 presents the levels of neutrophils in individuals with HIV-Malaria coinfection compared to those with HIV or malaria infection alone. The mean neutrophil percentage for individuals with HIV-Malaria coinfection was $51.71 \pm 9.44\%$. This was significantly lower than the mean neutrophil percentage of $59.23 \pm 11.50\%$ observed in individuals with HIV alone ($p < 0.001$). Similarly, the mean neutrophil percentage in individuals with malaria infection alone was $57.74 \pm 10.00\%$, which was also significantly higher than that in the HIV-Malaria coinfection group ($p = 0.001$). These results indicate a significant decrease in neutrophil levels in individuals with HIV-Malaria coinfection compared to those with either HIV or malaria infection alone.

| Parameter | HIV-Malaria coinfection | HIV | Malaria infection | p-value |
|-----------|-------------------------|-----|-------------------|---------|
|-----------|-------------------------|-----|-------------------|---------|

| | n=70 | n=70 | n=70 | |
|----------------|------------------|------------------|------------------|---------|
| | Mean ± SD | | | |
| Neutrophil (%) | 51.7089±9.440 | 59.2337±11.49514 | - | <0.001* |
| | 51.7089±9.440 | - | 57.7389±10.00316 | 0.001* |

*p-value is significant at p<0.05

Table 4 illustrates the relationships between the levels of TNF- α , IL-10, and neutrophils. The Pearson correlation analysis revealed a significant negative correlation between IL-10 and TNF- α ($r = -0.138$, $p = 0.045$), indicating that higher IL-10 levels were associated with lower TNF- α levels. However, the correlation between IL-10 and neutrophils was not significant ($r = 0.099$, $p = 0.153$). Conversely, a significant negative correlation was observed between TNF- α and neutrophils ($r = -0.304$, $p < 0.001$), suggesting that higher TNF- α levels were associated with lower neutrophil percentages. These findings highlight significant interrelationships among these biomarkers, with TNF- α showing notable associations with both IL-10 and neutrophil levels.

| | IL-10 (pg/ml) | TNF- α (pg/ml) | NEUTROP HILS (%) |
|--|------------------|--------------------------|---------------------|
|--|------------------|--------------------------|---------------------|

| | | | | |
|-----------------------|---------------------|--------|---------|---------|
| IL-10 (pg/ml) | Pearson Correlation | 1 | -.138* | .099 |
| | Sig. (2-tailed) | | .045 | .153 |
| | N | 210 | 210 | 210 |
| TNF- α (pg/ml) | Pearson Correlation | -.138* | 1 | -.304** |
| | Sig. (2-tailed) | .045 | | .000 |
| | N | 210 | 210 | 210 |
| NEUTROPHILS (%) | Pearson Correlation | .099 | -.304** | 1 |
| | Sig. (2-tailed) | .153 | .000 | |
| | N | 210 | 210 | 210 |

*. Correlation is significant at the 0.05 level (2-tailed).

**. Correlation is significant at the 0.01 level (2-tailed).

4.0 DISCUSSION OF FINDINGS

The interplay between HIV and malaria presents a complex challenge to global health, particularly in regions where both infections are prevalent. Each disease exerts significant immunological and physiological impacts, and their co-occurrence could potentially exacerbate the severity of both conditions. Tumor Necrosis Factor-alpha (TNF- α), Interleukin-10 (IL-10), and neutrophil counts are critical biomarkers in understanding the immune response and inflammation associated with these infections[17][18][19]. TNF- α is a pro-inflammatory cytokine that plays a crucial role in the immune response but can also contribute to disease pathology when dysregulated. IL-10, an anti-inflammatory cytokine, often acts to counterbalance inflammation but may also influence disease outcomes through its immunosuppressive effects.

Neutrophils, the most abundant white blood cells, are central to the body's acute inflammatory response and their levels can reflect ongoing inflammatory processes.

Table 1 shows that individuals with HIV-malaria coinfection had a mean TNF- α level of 27.67 pg/ml, which is significantly higher compared to those with HIV alone (11.20 pg/ml) and malaria infection alone (13.23 pg/ml). This elevated TNF- α level in co-infected individuals aligns with several studies highlighting the enhanced inflammatory response in co-infected patients. For instance, previous research has demonstrated that co-infection with HIV and malaria leads to an increased production of pro-inflammatory cytokines, including TNF- α , compared to single infections [19][20][21].

The elevated TNF- α in HIV-malaria coinfection could be attributed to the synergistic effect of these infections on the immune system. Both HIV and malaria independently stimulate TNF- α production through different pathways. HIV infection triggers TNF- α production through the activation of macrophages and dendritic cells by the virus, while malaria induces TNF- α release primarily through the recognition of Plasmodium antigens by immune cells [22]. The combination of these stimuli in coinfection may lead to an exacerbated inflammatory response, with TNF- α contributing to both increased immune activation and potential immunopathology.

As indicated in Table 2, the mean IL-10 level in individuals with HIV-malaria coinfection was 18.74 pg/ml, which was not significantly different from the IL-10 levels observed in individuals with HIV alone (20.24 pg/ml) but was significantly lower compared to those with malaria infection alone (25.86 pg/ml). This discrepancy in IL-10 levels is noteworthy as it contrasts with some studies which have shown elevated IL-10 levels in HIV-malaria coinfection [21].

The observed lower IL-10 levels in coinfected individuals might be indicative of a dysregulated or exhausted anti-inflammatory response. In the context of co-infection, the immune system may be overwhelmed by the high inflammatory burden, leading to suboptimal IL-10 production.

Molecularly, the interaction between HIV and malaria could disrupt the signaling pathways responsible for IL-10 production. For instance, HIV-induced changes in the function of regulatory T cells and monocytes may impair the ability to produce IL-10 adequately in response to malaria infection [24]. This imbalance could result in a less effective counter-regulatory mechanism against the elevated TNF- α levels observed in these patients.

Table 3 presents data showing that the mean neutrophil percentage in individuals with HIV-malaria coinfection was 51.71%, significantly lower than in individuals with HIV alone (59.23%) but not significantly different from those with malaria infection alone (57.74%). This finding is consistent with some studies suggesting that neutrophil counts can be altered in co-infections, with a trend towards reduced neutrophil levels in complex infections [25][26].

The lower neutrophil levels observed in HIV-malaria coinfection could be attributed to the immunosuppressive effects of HIV. HIV infection can lead to neutrophil apoptosis and impaired neutrophil function, which may be exacerbated when combined with malaria [27]. On the other hand, malaria can also cause neutrophil sequestration in the spleen, leading to lower circulating neutrophil counts. The combined effects of HIV-induced neutropenia and malaria-induced sequestration might result in the observed neutrophil levels in coinfecting individuals.

Table 4 explores the correlations between TNF- α , IL-10, and neutrophil levels. A significant negative correlation was observed between TNF- α and IL-10 ($r = -0.138$, $p = 0.045$), suggesting that higher TNF- α levels are associated with lower IL-10 levels. Additionally, TNF- α levels were negatively correlated with neutrophil percentages ($r = -0.304$, $p < 0.001$), indicating that higher TNF- α levels are associated with lower neutrophil counts. Conversely, IL-10 and neutrophil levels showed a weak positive correlation ($r = 0.099$, $p = 0.153$), which was not statistically significant.

The significant inverse correlation between TNF- α and IL-10 supports the hypothesis of a disrupted balance between pro-inflammatory and anti-inflammatory responses in coinfecting individuals. Elevated TNF- α may suppress IL-10 production, leading to a less effective anti-inflammatory response. The negative correlation between TNF- α and neutrophils suggests that high TNF- α levels could be associated with neutrophil dysfunction or apoptosis. This correlation highlights the potential impact of TNF- α on neutrophil dynamics, further emphasizing the complex interplay between inflammation and immune cell function in HIV-malaria coinfection.

5.0 CONCLUSION

This study revealed significant differences in the levels of TNF- α , IL-10, and neutrophils among individuals with HIV-Malaria coinfection compared to those with HIV or malaria alone. Notably, TNF- α levels were markedly elevated in the HIV-Malaria coinfection group compared to the other groups, while IL-10 levels were significantly higher in individuals with malaria alone. Neutrophil percentages were significantly lower in the HIV-Malaria coinfection group compared to the HIV-only group. Correlation analyses indicated a significant inverse relationship between TNF- α and neutrophils, while IL-10 was negatively correlated with TNF- α .

6.0 RECOMMENDATION

Based on the study's findings, it is recommended that clinicians consider the elevated levels of TNF- α and altered neutrophil counts in individuals with HIV-Malaria coinfection when devising treatment plans. Enhanced monitoring and targeted therapeutic interventions to address the inflammatory responses may improve patient outcomes. Further research is also recommended to explore the mechanisms underlying the observed correlations and their potential impact on disease progression and management.

Ethical Approval and Consent

To address the ethical considerations of this study, approval was obtained from the Edo state's Ministry of Health's Ethics Review Board. The research adhered strictly to the ethical guidelines and principles set forth by the Ministry and the board and aligned with internationally recognized standards, such as the Declaration of Helsinki. Every aspect of the research involving human subjects was conducted with the highest respect for their rights, dignity, and well-being. Informed consent was carefully obtained from all participants before their involvement, ensuring their voluntary participation and clear understanding of the research objectives, procedures, and potential risks.

Disclaimer (Artificial intelligence)

Author (s) hereby declare that generative AI technologies such as large language models, etc. have been used during the writing or editing of manuscript. This explanation will include the name, version, model and source of the generative AI technology and as well as all input prompt provided to the generative AI technology

1. Open AI's ChatGPT-4.1 and Perplexity

2. Laptop and Phone

3. Summarise, Paraphrase and correct grammatical errors

REFERENCES

1. McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. *Trans R Soc Trop Med Hyg.* 1983;77(2):232-244. doi:10.1016/0035-9203(83)90081-0.
2. Elime FE, Nkenfou CN, Sosso SM, Kouamouo J, Moyou RS, Torimiro JN. Prevalence of HIV and malaria co-infection in Nkongsamba, Cameroon. *J Infect DisEpidemiol.* 2019;5(1):1-7. doi:10.23937/2474-3658/1510067.
3. Antonio-Nkondjio C, Sonhafouo-Chiana N, Ngadjeu CS, Doumbe-Belisse P, Talipouo A, Djamouko-Djonkam L, et al. Review of the evolution of insecticide resistance in main malaria vectors in Cameroon from 1990 to 2017. *Parasites Vectors.* 2019;12(1):1-15. doi:10.1186/s13071-019-3789-y.
4. MassodaTonye SAG, Kouambeng C, Wounang R, Vounatsou P. Challenges of DHS and MIS to capture the entire pattern of malaria parasite risk and intervention effects in countries with different ecological zones: The case of Cameroon. *Malar J.* 2018;17(1):1-12. doi:10.1186/s12936-018-2415-7.
5. Muema DM, Ndungu FM, Kinyanjui SM, Berkley JA. Effect of HIV infection on the acute antibody response to malaria antigens in children: An observational study. *Malar J.* 2011;10(1):1-8. doi:10.1186/1475-2875-10-260.
6. Szondy Z, Pallai A. Transmembrane TNF- α reverse signaling leading to TGF- β production is selectively activated by TNF targeting molecules: Therapeutic implications. *Pharmacol Res.* 2017;115:124-132. doi:10.1016/j.phrs.2016.11.021.

7. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. *Nat Immunol.* 2007;8(9):931-941. doi:10.1038/ni1504.
8. Kolaczowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol.* 2013;13(3):159-175. doi:10.1038/nri3399.
9. Hsieh CH, Frink M, Hsieh YC, Kan WH, Hsu JT, Schwacha MG, et al. The role of CD4+ T cells in traumatic injury-induced pulmonary apoptosis. *J Leukoc Biol.* 2008;83(3):534-544. doi:10.1189/jlb.0707525.
10. Lin PL, Lore K. Granulocytes in tuberculosis: Whipping up a storm. *J Leukoc Biol.* 2017;101(1):79-81. doi:10.1189/jlb.4ce0816-357r.
11. Ejigu S, Haile D, Solomon Y. Effect of malaria and HIV/AIDS co-infection on red blood cell indices and its relation with the CD4 level of patients on HAART in Bench Sheko Zone, Southwest Ethiopia. *PLoS One.* 2022;17(3). doi:10.1371/journal.pone.0263865.
12. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. *PLoS One.* 2017;12(3). doi:10.1371/journal.pone.0174233.
13. Gumel DK, Ibrahim A, Olayinka AT, Ibrahim MS, Balogun MS, Dahiru A, et al. HIV-Malaria co-infection and its determinants among patients attending antiretroviral treatment clinic in Zaria, Kaduna state, Nigeria. *J IntervEpidemiol Public Health.* 2021;4(1). doi:10.37432/jieph.2021.4.1.31.
14. Farney JK, Mamedova LK, Godsey BH, Bradford BJ. Technical note: Validation of an ELISA for measurement of tumor necrosis factor alpha in bovine plasma. *J Dairy Sci.* 2011;94(7):3504-9. doi:10.3168/jds.2010-4082.
15. Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, et al. The multifaceted nature of IL -10 : regulation , role in immunological homeostasis and its relevance to cancer , COVID -19 and post-COVID conditions. *FrontImmunol.* 2023 ;14 .doi:10 .3389/fimmu .2023 .1161067.
16. Astrand A, Wingren C, Walton C, Mattsson J, Agrawal K, Lindqvist M, et al. A comparative study of blood cell count in four automated hematology analyzers : An evaluation of the impact of preanalytical factors. *PLOS ONE.* 2024 ;19(5):e0301845. doi:10 .1371/journal.pone .0301845.
17. Alves MT, Simões R, Pestana RMC, de Oliveira AN, Oliveira HHM, Soares CE, et al. Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast

- Cancer Patients in a One-Year Follow-Up Study. *ImmunolInvestig.* 2022;51(4):883–98. doi:10.1080/08820139.2021.1882486.
18. Li Q, Li X, Quan H, Wang Y, Qu G, Shen Z, He C. IL-10^{-/-} Enhances DCs Immunity Against *Chlamydia psittaci* Infection via OX40L/NLRP3 and IDO/Treg Pathways. *Front Immunol.* 2021;12:645653. doi:10.3389/fimmu.2021.645653.
 19. Pocino K, Carnazzo V, Stefanile A, Basile V, Guerriero C, Marino M, et al. Tumor Necrosis Factor-Alpha: Ally and Enemy in Protean Cutaneous Sceneries. *Int J Mol Sci.* 2024;25(14):7762. doi:10.3390/ijms25147762.
 20. Ademola SA, Bamikole OJ, Amodu OK. Is TNF alpha a mediator in the co-existence of malaria and type 2 diabetes in a malaria endemic population? *Front Immunol.* 2023;14:1028303. doi:10.3389/fimmu.2023.1028303.
 21. Kotepui M, Mala W, Kwankaew P, Kotepui KU, Masangkay FR, Wilairatana P. Distinct cytokine profiles in malaria coinfections: A systematic review. *PLoS Negl Trop Dis.* 2023;17(1):e0011061. doi:10.1371/journal.pntd.0011061.
 22. Nosik M, Belikova MG, Ryzhov K, Avdoshina D, Sobkin A, Zverev V, Svitich O. Unique Profile of Proinflammatory Cytokines in Plasma of Drug-Naïve Individuals with Advanced HIV/TB Co-Infection. *Viruses.* 2023;15(6):1330. doi:10.3390/v15061330.
 23. López C, Yepes-Pérez Y, Hincapié-Escobar N, Díaz-Arévalo D, Patarroyo MA. What Is Known about the Immune Response Induced by *Plasmodium vivax* Malaria Vaccine Candidates? *Front Immunol.* 2017;8:126. doi:10.3389/fimmu.2017.00126.
 24. Edwards CL, Ng SS, de Labastida Rivera F, Corvino D, Engel JA, Montes de Oca M, et al. Human IL-10⁻producing Th1 cells exhibit a molecular signature distinct from Tr1 cells in malaria. *J Clin Invest.* 2023;133(1). doi:10.1172/JCI153733.
 25. Rajamanickam A, Pavan Kumar N, Nancy P A, Selvaraj N, Munisankar S, MariamRenji R V et al. Dynamic Changes in Neutrophil Counts and Neutrophil Granular Protein Levels in Convalescent COVID-19 Patients. *Arch Clin Biomed Res.* 2022;06(02). doi:10.26502/acbr.50170253.
 26. Takele Y, Adem E, Mulaw T, Müller I, Cotton JA, Kropf P. Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV. *PLoS Negl Trop Dis.* 2022;16(8):e0010681. doi:10.1371/journal.pntd.0010681.
 27. Alemu A, Shiferaw Y, Addis Z, Mathewos B, Birhan W. Effect of malaria on HIV/AIDS transmission and progression. *Parasites Vectors.* 2013;6(1):18. doi:10.1186/1756-3305-6-18.